Another Hindrance to Gene Therapy?
By Tim Silcott – Gene Therapy has been a top topic in life science for discussion in the past few years, with many companies delving into the area. Now that the field is maturing, we are seeing some setbacks from some of the top entrants in the space. Given there are so many different viral modalities and cell therapies used in Gene Therapy, it’s only a matter of time before we know which ones will truly succeed.
Shares of Spark Therapeutics, the most advanced gene therapy company in a growing field, were badly dented this morning after the Pfizer partner noted that one of 7 patients treated with their hemophilia B treatment experienced an immune response to the viral delivery vehicle they use.
That’s exactly what you don’t want to see in a gene therapy study, especially one this small, and Spark’s shares dropped 17% in a nasty reaction.